Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: Modelling study from the hospital perspective in Germany

PharmacoEconomics

Volumn 24, Issue 6, 2006, Pages 571-591

  Schädlich, Peter K ^a,g   Kentsch, Michael ^b   Weber, Manfred ^c   Kämmerer, Wolfgang ^d   Brecht, Josef Georg ^a   Nadipelli, Vijay ^e   Huppertz, Eduard ^f  

^a InForMed GmbH Outcomes Research and Health Economics   (Germany)

^b Clinical Center Itzehoe   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d Hospital Pharmacy   (Germany)

^e BAYER PHARMA AG   (Germany)

^f SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^g InForMed GmbH Outcomes Research and Health Economics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GERMANY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DRUG COSTS; ENOXAPARIN; GERMANY; HEMORRHAGE; HOSPITALS; HUMANS; MODELS, ECONOMIC; RANDOMIZED CONTROLLED TRIALS; THROMBOEMBOLISM;

EID: 33745066089     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624060-00005     Document Type: Article

References (58)

1. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-5
2. Haas S, Haas P. Niedermolekulare Heparine. Die Anwendung in Klinik und Praxis. 2. Auflage. Steinen: ZETT-Verlag, 1999
3. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. The Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800
4. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. Circulation 1996; 93: 2212-45
5. Bergqvist D, Jendteg S, Johansen L, et al. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined population in Sweden. Ann Intern Med 1997; 126: 454-7
6. Schädlich PK, Brecht JG, Huppertz E. Treatment costs of venous thromboembolic complications in acutely ill medical patients in Germany. Perfusion 2003; 16: 141-52
7. Gesetz zur Einführung des diagnose-orientierten Fallpauschalensystems für Krankenhäuser (Fallpauschalengesetz - FPG) vom 23. April 2002. BGBl I 2002: 1412-37
8. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease: THE-PRINCE Study Group. Am Heart J 2003; 145: 614-21
9. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98
10. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-9
11. Schädlich PK, Kämmerer W, Kentsch M, et al. Wirtschaftlichkeit der Prophylaxe thromboembolischer Komplikationen mit Enoxaparin bei internistischen Patienten: Einfluss auf die Kostensituation im Krankenhaus. Krankenhauspharmazie 2004; 25: 316-25
12. Bundesinstitut für Arzneimittel und Medizinprodukte - BfArM (Federal Institute for Drugs and Medical Devices, the German pharmaceutical regulatory authority). Zulassungsbescheid der Indikationserweiterung für Clexane® 40 mg und für Clexane® multidose 100mg/ml zur Primärprophylaxe tiefer Venenthrombose bei nicht-chirurgischen Patienten. Bonn: BfArM, 2000 March
13. Lamy A, Wang X, Kent R, et al. Economic evaluation of the MEDENOX trial: a Canadian perspective. Can Respir J 2002; 9: 169-77
14. Pechevis M, Detournay B, Pribil C, et al. Economic evaluation of enoxaparin vs placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value Health 2000; 3: 389-96
15. Nuijten MJC, Villar Antoñanzas F, Kosa J, et al. Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in Spain. Value Health 2003; 6: 126-36
16. Lloyd AC, Anderson PM, Quinlan DJ, et al. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. J Med Econ 2001; 4: 99-113
17. de Lissovoy G, Subedi P. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective. Am J Manag Care 2002; 8: 1082-8
18. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the Prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 2000; 86 (12B): 48M-52M
19. Brecht JG, Jenke A, Köhler ME, et al für den Arbeitskreis Pharmakoökonomie der Deutschen Gesellschaft für Klinische Pharmakologie und Therapie e.V. Empfehlungen der Deutschen Gesellschaft für Klinische Phamakologie und Therapie zur Durchführung und Bewertung pharmakoökonomischer Studien. Med Klin 1995; 90: 541-6
20. Bundesministerium des Innern - BMI. Bundes-Angestelltentarifvertrag (BAT) vom 23. Februar 1961, zuletzt geändert durch 78. Ä nderungstarifvertrag vom 31. Januar 2003. Berlin: BMI, 2003
21. Schönfeld W. Lexikon für das Lohnbüro - Ausgabe 2003. Arbeitslohn, Lohnsteuer und Sozialversicherung von A-Z. 45. Auflage. München: Jehle Rehm, 2003
22. Gebührenordnung für Ärzte (GOÄ). Stand der Ausgabe 1.1.2003. Köln: Deutscher Ärzte-Verlag, 2003
23. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein-thrombosis in major orthopaedic surgery. JAMA 1987; 257: 203-8
24. Oster G, Tuden RL, Colditz GA. Prevention of venous thromboembolism after general surgery: cost-effectiveness analysis of alternative approaches to prophylaxis. Am J Med 1987; 82: 889-99
25. Detournay B, Planes A, Vochelle N, et al. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics 1998; 13 (1 Pt 1): 81-9
26. Attanasio E, Russo P, Carunchio G, et al. Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer: a cost-effectiveness analysis. Pharmacoeconomics 2001; 19: 57-68
27. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121: 877-905
28. Dalen JE. Pulmonary embolism: what have we learned since Virchow? Treatment and prevention. Chest 2002; 122: 1801-17
29. Elliott CG, Goldhaber SZ, Visani L, et al. Chest radiographs in acute pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. Chest 2000; 118: 33-8
30. Alexander JK. Pulmonary embolism. In: Beers MH, Berkow R, editors. The Merck manual of diagnosis and therapy. 17th ed. Whitehouse Station (NJ): Merck & Co Inc, 2003: Chapter 72 [online]. Available from URL: http://www.merck.com/pubs/mmanual/section6/chapter72/72a.htm [Accessed 2003 Mar 6]
31. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S-21S
32. Levine MN. Thrombolytic therapy for venous thromboembolism. Clin Chest Med 1995; 16: 321-8
33. Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002; 162: 2537-41
34. Gould MK, Dembitzer AS, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9
35. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62
36. Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep vein thrombosis. Ann Intern Med 1998; 128: 663-7
37. de Valois JC, van Schaik CC, Verzijlbergen F, et al. Contrast venography: from gold standard to 'golden backup' in clinically suspected deep vein thrombosis. Eur J Radiol 1990; 11: 131-7
38. Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin. Leitlinien zur Diagnostik und Therapie der Venenthrombose und Lungenembolie. Stand Januar 2002. VASA 2002; 31 Suppl. 60: 1-19
39. Torbicki A, van Beek EJR, et al. Task force report: guidelines on diagnosis and management of acute pulmonary embolism. European Society of Cardiology Task Force on Pulmonary Embolism. Eur Heart J 2000; 21: 1301-36
40. Selvin S. Statistical analysis of epidemiologic data. 2nd ed. New York: Oxford University Press, 1996
41. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of healthcare programmes. 2nd ed. Oxford (UK): Oxford University Press, 1997
42. Bronstein IN, Semendjajew KA, Grosche G, et al. Teubnertaschenbuch der mathematik. Stuttgart: Teubner, 1996
43. Schädlich PK, Brecht JG. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany: economic evaluation of the prevention of relapse with acamprosate in the management of alcoholism (PRAMA) study. Pharmacoeconomics 1998; 13 (6): 719-30
44. Schädlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction: economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 1998; 14 (6): 654-69
45. Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17 (1): 37-52
46. Kleijnen JPC, van Groenendal W. Simulation: a statistical perspective. Chichester: John Wiley & Sons, 1992
47. Fishman G. Monte Carlo: concepts, algorithms, and applications. New York: Springer, 1996
48. Hartung J, Elpelt B, Klösener KH. Statistik: Lehr- und Handbuch der angewandten Statistik. 13. Auflage. München: Oldenbourg, 2002
49. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness: from the Enoxaparin in Medicine Study Group (EMSG). Thromb Haemost 1996; 76: 529-34
50. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in nonsurgical patients: epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). The PRIME Study Group. Haemostasis 1996; 26 Suppl. 2: 49-56
51. Aventis Pharma Deutschland GmbH. Fachinformation zu Clexane® 40 mg und Clexane® multidose 100 mg/ml. Bad Soden am Taunus: Aventis Pharma Deutschland GmbH, 2002 Dec
52. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26 Suppl. 1: 31-8
53. Statistisches Bundesamt, editor. Gesundheitswesen. Fachserie 12, Reihe 6.3. Kostennachweis der Krankenhäuser 2001. Stuttgart: Metzler-Poeschel, 2003
54. Gerste B, Schellschmidt H, Rosenow C. Personal im Krankenhaus: Entwicklungen 1991 bis 1999. In: Arnold M, Klauber J, Schellschmidt H, editors. Krankenhaus-Report 2001. Stuttgart: Schattauer, 2002: 13-46
55. Offermanns M. Krankenhaus Barometer - Herbstumfrage 2002. Düsseldorf: Deutsches Krankenhausinstitut e.V., 2003
56. Blum K. Entlastungspotenziale im Pflegedienst der Krankenhäuser. Das Krankenhaus 2003; 95: 459-62
57. Verordnung zum Fallpauschalensystem für Krankenhäuser (KFPV) vom 19. September 2002. BGBl, 2002: 3674-726
58. Schädlich PK, Kentsch M, Weber M, et al. Economic evaluation of the MEDENOX (prophylaxis in MEDical patients with ENOXaparin) trial from the perspective of hospitals in Germany: results of a subgroup analysis [abstract no. PCV 39]. Value Health 2003; 6: 657